These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15096050)

  • 21. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.
    Cole NB; Murphy DD; Grider T; Rueter S; Brasaemle D; Nussbaum RL
    J Biol Chem; 2002 Feb; 277(8):6344-52. PubMed ID: 11744721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson's disease.
    Lee JC; Langen R; Hummel PA; Gray HB; Winkler JR
    Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16466-71. PubMed ID: 15536128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oligomers of Parkinson's Disease-Related α-Synuclein Mutants Have Similar Structures but Distinctive Membrane Permeabilization Properties.
    Stefanovic AN; Lindhoud S; Semerdzhiev SA; Claessens MM; Subramaniam V
    Biochemistry; 2015 May; 54(20):3142-50. PubMed ID: 25909158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
    El-Agnaf OM; Jakes R; Curran MD; Wallace A
    FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity.
    Wersinger C; Prou D; Vernier P; Niznik HB; Sidhu A
    Mol Cell Neurosci; 2003 Sep; 24(1):91-105. PubMed ID: 14550771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
    Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
    J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
    Volles MJ; Lansbury PT
    Biochemistry; 2002 Apr; 41(14):4595-602. PubMed ID: 11926821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural determinants of PLD2 inhibition by alpha-synuclein.
    Payton JE; Perrin RJ; Woods WS; George JM
    J Mol Biol; 2004 Apr; 337(4):1001-9. PubMed ID: 15033366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helical alpha-synuclein forms highly conductive ion channels.
    Zakharov SD; Hulleman JD; Dutseva EA; Antonenko YN; Rochet JC; Cramer WA
    Biochemistry; 2007 Dec; 46(50):14369-79. PubMed ID: 18031063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
    Rochet JC; Conway KA; Lansbury PT
    Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. alpha-Synuclein membrane interactions and lipid specificity.
    Jo E; McLaurin J; Yip CM; St George-Hyslop P; Fraser PE
    J Biol Chem; 2000 Nov; 275(44):34328-34. PubMed ID: 10915790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding.
    Ghosh D; Sahay S; Ranjan P; Salot S; Mohite GM; Singh PK; Dwivedi S; Carvalho E; Banerjee R; Kumar A; Maji SK
    Biochemistry; 2014 Oct; 53(41):6419-21. PubMed ID: 25268550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein.
    Rospigliosi CC; McClendon S; Schmid AW; Ramlall TF; Barré P; Lashuel HA; Eliezer D
    J Mol Biol; 2009 May; 388(5):1022-32. PubMed ID: 19345692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR.
    Ramakrishnan M; Jensen PH; Marsh D
    Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
    Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
    J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states.
    Fredenburg RA; Rospigliosi C; Meray RK; Kessler JC; Lashuel HA; Eliezer D; Lansbury PT
    Biochemistry; 2007 Jun; 46(24):7107-18. PubMed ID: 17530780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.
    Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G
    FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-synuclein and familial variants affect the chain order and the thermotropic phase behavior of anionic lipid vesicles.
    Pantusa M; Vad B; Lillelund O; Kjær L; Otzen D; Bartucci R
    Biochim Biophys Acta; 2016 Sep; 1864(9):1206-1214. PubMed ID: 27177693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.